Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 13138Triple Negative Breast Neoplasms 1150Neoplasms 750Ovarian Neoplasms 680Neoplasm Metastasis 590Lung Neoplasms 582Colorectal Neoplasms 581Prostatic Neoplasms 560Carcinoma, Non-Small-Cell Lung 536Pancreatic Neoplasms 380Melanoma 366Stomach Neoplasms 350Colonic Neoplasms 330Motor Activity 285Breast Neoplasms, Male 285Carcinoma, Intraductal, Noninfiltrating 277Uterine Cervical Neoplasms 267Head and Neck Neoplasms 266Endometrial Neoplasms 256Carcinoma, Renal Cell 216Sarcoma 204Urinary Bladder Neoplasms 192Squamous Cell Carcinoma of Head and Neck 192Lymphedema 190Esophageal Neoplasms 189Breast Carcinoma In Situ 189Brain Neoplasms 183Fatigue 166Carcinoma, Ovarian Epithelial 151Small Cell Lung Carcinoma 148

Interventions

eribulin 1disitamab vedotin 1RC48 antibody 1Paclitaxel 1Gemcitabine 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
HER2-low Breast Cancer × Breast × Clear all
NCT07446452 2026-03-03

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
37 enrolled
Breast

HER2-low Breast Cancer

NCT06957886 2026-01-21

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Recruiting
566 enrolled
Breast

HER2-low Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡